AstraZeneca
patient disposition | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
September 2021
Slide
10 of 34
Related slides by other companies
argenx SE
Investor Conference
January 2024
we aim to address the unseen suffering in | argenx SE
Mednow
Investor Presentation
May 2022
investment highlights forecasts show strong growth calendar full year forecast calendar full year forecast revenue revenue gross margin gross margin negative adjusted margin million adjusted active patients define with active in last months active patients define with active in last months | Mednow
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase no no treatment related no aes leading to dose reduction or discontinuation no treatment related dizziness treatment related adverse events in patient all treated patients nausea alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting including source a toxicity | Nuvalent
OKYO Pharma
Results
June 2023
limits of current standard of care | OKYO Pharma
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io